Treatment with bexarotene, a compound that increases apolipoprotein-E, provides no cognitive benefit in mutant APP/PS1 mice

Molecular Neurodegeneration

Volumn 8, Issue 1, 2013, Pages

  Laclair, Katherine D ^a   Manaye, Kebreten F ^b   Lee, Dexter L ^b   Allard, Joanne S ^b   Savonenko, Alena V ^a   Troncoso, Juan C ^a   Wong, Philip C ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HOWARD UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; APOE; Bexarotene; Cognition; Mouse model; RXR agonist

Indexed keywords

ABC TRANSPORTER A1; AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; BEXAROTENE; DIMETHYL SULFOXIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; FEMALE; MALE; MEMORY; MOUSE; NONHUMAN; UPREGULATION;

ALZHEIMER DISEASE; ANIMALS; ANTICARCINOGENIC AGENTS; APOLIPOPROTEINS E; ATP-BINDING CASSETTE TRANSPORTERS; BEHAVIOR, ANIMAL; BLOTTING, WESTERN; DISEASE MODELS, ANIMAL; FEMALE; MALE; MEMORY; MICE; MICE, MUTANT STRAINS; PLAQUE, AMYLOID; TETRAHYDRONAPHTHALENES;

MUS;

EID: 84878816554     PISSN: None     EISSN: 17501326     Source Type: Journal    
DOI: 10.1186/1750-1326-8-18     Document Type: Article

References (24)

1. Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. Jankowsky JL, Fadale DJ, Anderson J, Xu GM, Gonzales V, Jenkins NA, Copeland NG, Lee MK, Younkin LH, Wagner SL, Younkin SG, Borchelt DR, Hum Mol Genet 2004 13 2 159 70 14645205 (Pubitemid 38111354)
2. Elevated plasma triglyceride levels precede amyloid deposition in Alzheimer's disease mouse models with abundant a beta in plasma. Burgess BL, McIsaac SA, Naus KE, Chan JY, Tansley GH, Yang J, Miao F, Ross CJ, van Eck M, Hayden MR, van Nostrand W, St George-Hyslop P, Westaway D, Wellington CL, Neurobiol. Dis. 2006 24 1 114 27 10.1016/j.nbd.2006.06.007 16899370 (Pubitemid 44416212)
3. Neurobiology of Alzheimer's disease. Wong PC, Savonenko A, Li T, Price DL, In Basic neurochemistry, Oxford: Elsevier Inc: Eighth Edition. Edited by Brady S, Albers P 2012 815 828
4. ApoE promotes the proteolytic degradation of abeta. Jiang Q, Lee CY, Mandrekar S, Wilkinson B, Cramer P, Zelcer N, Mann K, Lamb B, Willson TM, Collins JL, Richardson JC, Smith JD, Comery TA, Riddell D, Holtzman DM, Tontonoz P, Landreth GE, Neuron 2008 58 5 681 93 10.1016/j.neuron.2008.04.010 18549781 (Pubitemid 351778466)
5. Apolipoprotein E, especially apolipoprotein E4, increases the oligomerization of amyloid β peptide. Hashimoto T, Serrano-Pozo A, Hori Y, Adams KW, Takeda S, Banerji AO, Mitani A, Joyner D, Thyssen DH, Bacskai BJ, Frosch MP, Spires-Jones TL, Finn MB, Holtzman DM, Hyman BT, J Neurosci 2012 32 43 15181 92 10.1523/JNEUROSCI.1542-12.2012 23100439
6. APOE is a major susceptibility gene for Alzheimer's disease. Roses AD, Saunders AM, Curr Opin Biotechnol 1994 5 6 663 667 10.1016/0958-1669(94)90091-4 7765750
7. Human ApoE isoforms differentially regulate brain amyloid-β peptide clearance. Castellano JM, Kim J, Stewart FR, Jiang H, DeMattos RB, Patterson BW, Fagan AM, Morris JC, Mawuenyega KG, Cruchaga C, Goate AM, Bales KR, Paul SM, Bateman RJ, Holtzman DM, Sci. Transl. Med 2011 3 89 89ra57 10.1126/scitranslmed. 3002156 21715678
8. Lipidation of apolipoprotein E influences its isoform-specific interaction with Alzheimer's amyloid beta peptides. Tokuda T, Calero M, Matsubara E, Vidal R, Kumar A, Permanne B, Zlokovic B, Smith JD, LaDu MJ, Rostagno A, Frangione B, Ghiso J, Biochem J. 2000 348 359 65 10.1042/0264-6021:3480359 10816430 (Pubitemid 30345209)
9. Deficiency of ABCA1 impairs apolipoprotein E metabolism in brain. Hirsch-Reinshagen V, Zhou S, Burgess BL, Bernier L, McIsaac SA, Chan JY, Tansley GH, Cohn JS, Hayden MR, Wellington CL, J Biol Chem. 2004 279 41197 41207 10.1074/jbc.M407962200 15269218 (Pubitemid 39287722)
10. ABCA1 is required for normal central nervous system ApoE levels and for lipidation of astrocyte-secreted apoE. Wahrle SE, Jiang H, Parsadanian M, Legleiter J, Han X, Fryer JD, Kowalewski T, Holtzman DM, J Biol Chem. 2004 279 40987 40993 10.1074/jbc.M407963200 15269217 (Pubitemid 39287699)
11. Transport pathways for clearance of human Alzheimer's amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system. Bell RD, Sagare AP, Friedman AE, Bedi GS, Holtzman DM, Deane R, Zlokovic BV, J Cereb Blood Flow Metab. 2007 27 909 918 17077814 (Pubitemid 46659038)
12. Production and characterization of astrocyte-derived human apolipoprotein E isoforms from immortalized astrocytes and their interactions with amyloid-beta. Morikawa M, Fryer JD, Sullivan PM, Christopher EA, Wahrle SE, DeMattos RB, O'Dell MA, Fagan AM, Lashuel HA, Walz T, Asai K, Holtzman DM, Neurobiol Dis. 2005 19 66 76 10.1016/j.nbd.2004.11.005 15837562 (Pubitemid 40544724)
13. ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models. Cramer P, Cirroto J, Wesson D, Lee CY, Karlo J, Zinn A, Casali B, Restivo J, Goebel W, James M, Brunden K, Wilson D, Landreth GE, Science 2012 23 335 1503 1506
14. Comment on "ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models. Fitz NF, Cronican AA, Lefterov I, Koldamova R, Science Tech. Comments 2013 340 924-c
15. Comment on "ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models. Price AR, Xu G, Siemienski ZB, Smithson LA, Borchelt DR, Golde TE, Felsenstein KM, Science Tech. Comments 2013 340 924-d
16. Comment on "ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models" Tesseur I, Lo AC, Roberfroid A, Dietvorst S, Van Broeck B, Borgers M, Gijsen H, Moechars D, Mercken M, Kemp J, D'Hooge R, De Strooper B, Science Tech. Comments 2013 340 924-e
17. Veeraraghavalu K, Zhang C, Miller S, Hefendehl JK, Rajapaksha TW, Ulrich J, Jucker M, Holtzman DM, Tanzi RE, Vassar R, Sisodia SS, Science Tech. Comments 2013 340 924-f
18. Augmented senile plaque load in aged female β-amyloid precursor protein-transgenic mice. Callahan MJ, Lipinski WJ, Bian F, Durham RA, Pack A, Walker LC, Am. J. Pathol. 2001 158 3 1173 1177 10.1016/S0002-9440(10)64064-3 11238065 (Pubitemid 32221809)
19. Overexpression of low density lipoprotein receptor in the brain markedly inhibits amyloid deposition and increases extracellular a-beta clearance. Kim J, Castellano JM, Jiang H, Basak JM, Parsadanian M, Pham V, Mason SM, Paul SM, Holtzman DM, Neuron 2009 64 632 644 10.1016/j.neuron.2009.11.013 20005821
20. Gender modulates the APOE 4 effect in healthy older adults: convergent evidence from functional brain connectivity and spinal fluid tau levels. Damoiseaux JS, Seeley WW, Zhou J, Shirer WR, Coppola G, Karydas A, Rosen HJ, Miller BL, Kramer JH, Greicius MD, J Neurosci 2012 32 24 8254 62 10.1523/JNEUROSCI.0305-12.2012 22699906
21. Attenuation of neuroinflammation and Alzheimer's disease pathology by liver x receptors. Zelcer N, Khanlou N, Clare R, Jiang W, Reed-Geaghan EG, Landreth GE, Vinters HV, Tontonoz P, Proc Natl Acad Sci USA 2007 104 25 10601 6 10.1073/pnas.0701096104 17563384 (Pubitemid 47185711)
22. Involvement of Iba1 in membrane ruffling and phagocytosis of macrophages/microglia. Ohsawa K, Imai Y, Kanazawa H, Sasaki Y, Kohsaka S, J. Cell Sci. 2000 113 3073 3084 10934045
23. Physiology of microglia. Kettenmann H, Hanisch U-K, Noda M, Verkhratsky A, Physiol. Rev. 2011 91 2 461 553 10.1152/physrev.00011.2010 21527731
24. CA3 NMDA receptors are required for the rapid formation of a salient contextual representation. McHugh TJ, Tonegawa S, Hippocampus 2009 19 1153 1158 10.1002/hipo.20684 19650121